Very Low-Dose Risperidone in First-Episode Psychosis: A Safe and Effective Way to Initiate Treatment
Table 3
Summary of the reports of extrapyramidal symptoms.
Number of participants experiencing symptoms at week 4 and week 8*
Cumulative number of participants experiencing symptoms during the study†
Extrapyramidal symptom
Baseline ()
Week 4 ()
Week 8 ()
Weeks 1–4 after baseline
Weeks 1–8 after baseline
Akathisia
3 (3.1%)
4 (6.4%)
1 (1.8%)
13
13
Mild
2
3
1
10
10
Moderate
1
1
0
3
3
Hypokinesia
2
2
Mild
0
0
0
1
1
Moderate
1
1
Rigidity
2 (2.1%)
11 (17.5%)
11 (20%)
31
34
Mild
2
8
10
24
26
Moderate
0
3
1
7
8
Tremor
3 (3.1%)
2 (3.2%)
5 (9.1%)
15
18
Mild
2
2
5
15
16
Moderate
1
0
0
0
2
Acute dystonia
Mild
0
0
0
0
0
Moderate
Dyskinesia
1
Mild
0
0
0
0
1
Moderate
0
*Extrapyramidal symptoms could be reported as mild, moderate, or severe; there were no reports of a severe reaction. †Patients who experienced symptoms at least once during the study period.
